Immunome Research
Open Access

Vaccines and Optic Neuritis: Consequence or Coincidence?

Justyna Roszkiewicz^1,2 and Yehuda Shoenfeld^{2,3* *}Correspondence: Yehuda Shoenfeld, Department of Immunology, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center (Affiliated to Tel-Aviv University), Tel-Hashomer 5265601, Tel Aviv, Israel,

Author info »

Introduction

Optic neuritis (ON) is an inflammatory demyelinating disease of the optic nerve. The typical clinical characteristics of ON include reduced visual acuity and peripheral vision, decreased perception of brightness accompanied by globe tenderness and pain during eye movement [1]. ON is infrequent disease, the incidence varies from 0.94 to 2.18 per 100 000 per year regarding the unilateral form of the disease, bilateral subtype of ON occurs even less often [2]. The pathogenesis of ON remains poorly characterized, although many facts combine in favor of autoimmune nature of this disorder. ON may develop in the course of several Central Nervous System (CNS) demyelinating autoimmune diseases, with MS as the leading cause (15%-20% of cases) [3], followed by Neuromyelitis Optica Spectrum Disorders (NMOSD), and Acute Disseminated Encephalomyelitis (ADEM). ON can be also inscribed in the course of systemic inflammatory connective tissue disorders, such as systemic lupus erythematosus (SLE), systemic sclerosis or Behcet's disease [4,5], although infrequently [4]. Furthermore, mechanisms underlying autoimmune reactions including Treg/Th17 cell imbalance [6], an abundance of proinflammatory cytokines [7], the presence of circulating autoantibodies combined with the underlying genetic background of autoimmunity (HLA- DQB1*06:02-HLA-DRB1*15:01 haplotype [8] were reported in ON patients. The etiology of most autoimmune processes is multi-factorial, combining genetic, immunological, hormonal and environmental factors forming the “mosaic of autoimmunity” [9]. Infectious antigens play a key role in this interplay, and ON, especially in the pediatric population, may be associated with a preceding infectious illness, both of viral and bacterial etiology [10], including influenza [11], mumps [12], varicella zoster [13], cytomegalovirus [14], herpesvirus-6 [15], Epstein–Barr virus [16] and mycoplasma pneumoniae [17]. In most cases, symptoms of ON begin after the patient had recovered from the infectious disease, suggesting an autoimmune reaction to the pathogen as a trigger of the inflammatory response. Several cases of ON following vaccination were also reported [10]. The aim of this study was to examine and determine the clinical characteristics of vaccination- related ON.

Materials and Methods

SA literature search was performed using MEDLINE [PubMed] database, employing as keywords: "optic neuritis"; "vaccine"; "vaccination"; "vaccine-associated". Article bibliographies were checked to ensure all studies and reports were included. Moreover, we conducted the Vaccine Adverse Event Reporting System (VAERS) database search for reports of ON onset following any type of vaccination, using "optic neuritis" and "optic neuritis retrobulbar" as the keywords. The analysis included the reports that were obtained in the period January 1990-January 2019. Based on the symptoms reported, we have classified ON cases into the following categories:

• Isolated ON

• ON preceding NMOSD

• ON preceding ADEM

• ON preceding MS

• ON in the course of other diseases

Results

Case reports and case series

An extensive literature review found 48 cases of vaccine-related ON reported in the years 1949-2018. From this group, the majority (32 cases) presented with the clinical features of isolated ON, followed by ON in course of NMOSD in 9 patients and ADEM in 6. ON generally occurred after the booster dose of the vaccine, although cases of the autoimmune phenomenon after the first dose of the vaccine were also noted. It is important to notice that the quality and detail of reported cases varied, mostly due to the indisputably long time interval between first and latest reports and therefore diagnostic capabilities discrepancy. Moreover, the observation time of individuals affected by ON was relatively short and did not exceed two years. Consequently, the incidence of patients in whom ON was the first symptom of the central nervous system inflammatory demyelinating disease might have been underestimated.

Isolated optic neuritis

Isolated ON occurred in 32 patients, equally often in women than in men. The time interval between the vaccination and the occurrence of the first ON symptoms ranged between 6 hours to 21 days with a mean number of 12.05 days. ON was most frequently associated with the vaccination against influenza (7 cases), followed by measles, mumps, rubella vaccine (MMR; 4 cases+ 1 without the mumps antigen), dyptheria, tetanus, pertussis vaccine(DTP; 4 cases), Hepatitis B Virus vaccine (HBV; 3 cases) and vaccines against Hepatitis A Virus (HAV), Varicella Zoster Virus (VZV), anthrax, rabies (2 cases each). In 4 cases ON was a result of multiple vaccinations (DTP+IPV, DTP+ smallpox, HAV+ typhoid fever). The course of ON was bilateral in 69% of cases, unilateral in 31% of them. Interestingly, the vaccine against influenza was associated with bilateral ON exclusively. The outcome of ON treatment was successful in the majority of patients: 56% fully regained their vision, in 12.5% partial improvement was observed. In 12.5% of the affected individuals, there was no recovery.

Optic neuritis preceding NMOSD

NMOSD (previously known as Devic’s disease) form a group of autoimmune, demyelinating disorders of CNS with typical clinical manifestations of optic neuritis and acute transverse myelitis attacks. Previously believed to be a variant of MS, it is now considered an independent disorder. The demyelination process in the course of NMOSD is associated with the presence of autoantibodies against aquaporin-4 (AQP4-IgGs). Nevertheless, AQP4-IgG seronegativity in 10%-25% of NMO patients suggests that there are several other factors involved in NMO immunopathogenesis, i.e., autoantibodies against aquaporin-1 (AQP1-Abs) and antibodies against myelin oligodendrocyte glycoprotein (MOG-IgGs) [18,19]. Post-vaccination ON led to NMOSD diagnosis in 9 patients, 4 men and 5 women. The time interval between vaccination and first symptoms of ON was significantly longer than in isolated ON, ranging from 3 days to 9 months with the mean of 99 days. All cases in which ON occurred after the period of one month were associated with HPV vaccination. HPV vaccine was also the leading cause of ON in this group: symptoms of NMOSD developed in 4 patients, followed by vaccines against pneumococcal infections, yellow fever, HBV, DTP, Japanese encephalitis (1 case each). The course of disease was unilateral in 5 patients and bilateral in 4. The presence of AQP4-IgG antibodies was confirmed in 2 out of 9 individuals, anti-MOG antibodies were positive in 3, although their incidence may be underestimated, as in 3 cases the results of the test were not reported. Although signs of recovery were observed in all affected patients, the clinical cause of the disease was more aggressive and therefore required intensified treatment regimen, consisting of steroids, plasma exchanges and disease-modifying antirheumatic drugs (DMARDs).

ON preceding ADEM

ADEM is an immune-mediated demyelinating CNS disorder, characterized clinically by new-onset polyfocal neurologic symptoms including encephalopathy, coupled with neuroimaging evidence of multifocal demyelination. ADEM is classically considered a monophasic illness, with the highest incidence in early childhood. As early as in the 18th-century temporal relationship with ADEM onset and infections was observed. Over a century later, an association of ADEM with vaccines, notably rabies, was reported [20]. In the literature we identified 6 cases of ON inscribed in the course of ADEM. The mean time interval between vaccination and ON was 20 days. Female to male ratio in ON-ADEM population was 1:1. The clinical course of ON was bilateral in 5 patients, unilateral in 1. Two cases of ON were reported as side effects of vaccines against influenza; rubella, rabies, HPV and MMR vaccines were related to 1 case of ON each.

Cases of ON reported in VAERS

VAERS, co administered by the Centers for Disease Control and Prevention (CDC) and United States Food and Drug Administration (FDA) is a passive surveillance system collecting reports of adverse effects following vaccination from healthcare providers, vaccine manufacturers and affected individuals themselves [21]. VAERS data include demographic information about vaccine recipients, specific vaccine received, details of experienced adverse effect and patients’ medical histories [22]. It is important to emphasize that VAERS has many limitations. To begin with, VAERS collects data on any adverse effect following vaccination, including coincidental ones and truly caused by the vaccine. The quality and completeness of VAERS reports is variable and many lack variable medical diagnoses. Moreover, mild reactions following vaccination are underrepresented in the database, serious ones on the other hand may be overreported by patients in response to intense media attention and increased public awareness [21].

In the VAERS database, we have identified 537 reports of vaccination-related ON, from which 448 were qualified for further analysis and 89 were excluded due to lack of final medical diagnosis. From the 448 VAERS reports 362 referred to single post-vaccination reaction cases (had unique VAERS identity number).

Isolated ON was the most frequently reported (229 cases), followed by ON proceeding of MS (85 cases: in 79 ON was the first symptom of MS, in 6 vaccinations led to disease exacerbation presenting as ON). In 20 cases ON occurred as the symptom of ADEM, in 14 appeared in the clinical spectrum of NMOSD. In 7 cases ON preceded the development of rheumatic disease (Behcet’s disease, rheumatoid arthritis, giant cell arteritis, SLE, macrophagic myofascitis, undifferentiated connective tissue disease), in 2 it was a prelude to other autoimmune diseases (Hashimoto’s thyrioditis, ulcerative colitis). 4 cases were related to the development of neurological impairment (Guilllain – Barre syndrome, HPV vaccination-associated neuro-immunopathogenic syndrome – HANS [23]), in one case autoimmune syndrome induced by adjuvants (ASIA) [24] was diagnosed. The vaccination – ON onset interval was considerably longer after aluminum-adjuvanted vaccines (mean 52.11 days,) in comparison to vaccines not enriched with this chemical element (mean 22.28 days).

Isolated ON

Isolated ON was reported 284 times, which correspond to 229 single cases of post-vaccination ON. ON was more likely to be observed after vaccination with viral vaccine (230 reports) than bacterial one (54 reports). Individuals affected were mainly of female gender (female: male ratio 2:1), the course of ON was unilateral in 104 cases and bilateral in 55. Vaccines most frequently associated with ON were influenza (63 reports), HBV (56 reports) and HPV (47 reports) (Figure 1). The mean time interval between vaccination and ON development was 25.83 days (Figure 2). Underlying allergic or autoimmune conditions were reported in 18 and 3 individuals from the affected population, respectively.

Figure 1: Vaccines associated with isolated optic neuritis reported in vaccine adverse effects reporting system.
Abbreviations: DTP: Diphtheria Tetanus Pertussis; DT: Diphtheria Tetanus; IPV: Inactivated Polio Vaccine; HiB: Haemophilus Influenza Type B; HAV: Hepatitis A Virus; HBV: Hepatitis B Virus; HPV: Human Papilloma Virus; MMR: Measles Mumps Rubella; Polio: Poliomyelitis.

Figure 2: Time interval between vaccination optic neuritis and symptoms of isolated optic neuritis according to vaccine adverse effects reporting system report.

ON associated with MS

ON preceding MS was reported 93 times, what corresponded to 85 clinical cases: 79 in which ON was the first symptom of developing MS and 6 in which vaccination led to MS exacerbation, presenting as ON. The vast majority of VAERS reports was associated with vaccinations against viral pathogens (85 reports), with the HBV vaccination (54 reports) as the leading cause, followed by HPV (10 reports) and Influenza (5 reports) (Figure 3). The time interval between the vaccination and ON development was significantly longer than in other cases of ON with the mean of 78.57 days (Figure 4). ON appeared more frequently in females than in males (65 versus 18 cases) and was mainly unilateral.

Figure 3: Vaccines associated with MS-related optic neuritis according to vaccine adverse effects reporting system reports.
Abbreviations: DTP: Diphtheria Tetanus Pertussis; Polio: Poliomyelitis; HAV: Hepatitis A Virus; HBV: Hepatitis B Virus; HPV: Human Papilloma Virus; MMR: Measles Mumps Rubella.

Figure 4: Time interval between vaccination optic neuritis and first symptoms of ms-optic neuritis according to vaccine adverse effects reporting system reports.

ON preceding ADEM

ON preceding ADEM was reported 30 times, what corresponds to 20 cases of this phenomenon. 16 out of 30 vaccination-related ON reports concerned multiple vaccinations. The vaccine most frequently associated with ON in this subgroup was DTP (6 reports), followed by HBV (5 reports) and Influenza (5 reports). The mean time interval between vaccination and development of ON was 18.66 days (Figure 5). There was no significant difference in ON cases sex distribution or course of the disease.

Figure 5: Time interval between vaccination optic neuritis and first symptoms of optic neuritis-adem according to vaccine adverse effects reporting system reports.

ON preceding NMOSD

ON appearing as part of NMOSD was reported 20 times, in 14 patients, 10 females and 4 males. The mean time interval between vaccination and ON was 41.93 days (Figure 6). Vaccination against viral pathogen preceded symptoms of NMOSD in 13 reports, in 7 the reported vaccine was against bacterial pathogen. The course of the disease was mainly bilateral (9 reports). There was no vaccine predominantly associated with NMOSD onset, ON was observed after HPV vaccination in 4 reports, after DTP in 3 and in two cases after HBV, influenza and meningococcal vaccines.

Figure 6: Time interval between vaccination optic neuritis and first symptoms optic neuritis neuromyelitis optica spectrum diseases according to vaccine adverse effects reporting system report.

Discussion

ON following vaccination, although frequently reported in the literature (Table 1) remains the phenomenon with elusive underlying mechanism. In our study we have observed that vaccination-related ON is more likely to develop after vaccines against viral pathogens and that different types of vaccines are associated with distinct ON-associated diseases. Isolated ON was mostly reported following vaccination against influenza, whereas in ON-MS HBV vaccine was the leading cause. Isolated ON was the most frequent manifestation of demyelinisation both in cases reported in the literature and in VAERS, although its incidence might have been overestimated, as MS may be diagnosed in this population even years after the first episode of ON [25]. Moreover, reports of many ON cases lacked the full antibody screening (anti-AQP4, anti-MOG, anti-ganglioside, anti-phosphatidylcholine [26]. The time interval between vaccination and symptoms of ON was shortest in the isolated ON subgroup, followed by ADEM and was significantly prolonged in cases of NMOSD and MS-ON, suggesting different factors involved in the pathogenesis of those clinical entities. We have also observed, that vaccines containing aluminum were associated with delayed onset of ON, in comparison to vaccines devoid of this adjuvant. Although numerous reports suggest that demyelination may be associated with various types of vaccines the epidemiological studies on that topic failed to show the association [27,28].

Table 1: Cases of vaccination-related optic neuritis reported in the medical literature.

Introduction of immunization programs is undoubtedly one of the greatest achievements in the history of medicine. Vaccinations have profoundly changed the spectrum of diseases affecting the human population and contributed to eradication or large reduction of many infectious disease cases (smallpox, poliomyelitis, and measles). However, nowadays vaccines are progressively becoming the victim of their own success, and many issues regarding their safety raise concerns. Neurological complications following vaccinations, although rare, are well-described phenomenon. The earliest descriptions of neurological complications after vaccinations comes from a report of a neuroparalytic syndrome after Pasteur’s rabies immunization in 1889 [29] and since then cases of seizures, GBS, peripheral neuropathy, encephalopathy and others have been recognized [30,31]. In the recent years the association of vaccines with autoimmune diseases is emerging as the new area of research. As autoimmune phenomena are usually documented within weeks following the vaccination, the plausible causal relationship between vaccination and development of autoimmunity is difficult to delineate and therefore a subject to reporting bias [32].

Moreover, as the overall risk of vaccination-related serious side effect, including autoimmune reactions, is immensely low (i.e. autoimmune mediated demyelinating disease-0.1%), collecting a representative study group for further research is unavailable.

Nevertheless, there are some examples in which the dubious link between vaccines and autoimmunity seems more than logical. In 1976 an outbreak of GBS followed immunization with the “swine flu” vaccine [33]. Similar causal relationship has been shown in transverse myelitis (after oral polio vaccine), in arthritis (following DTP and MMR vaccine) and in autoimmune thrombocytopenia (after MMR vaccine) [34]. In addition, a number of animal models enabled a better way of studying the cause and effect relationship between vaccines and autoimmunity. Vaccination of female mice with aluminum adjuvants and HPV vaccine led to behavioral abnormalities [35], immunization of dogs induced the production of 9 different autoantibodies including lupus-associated ones [36] and vaccination of diabetic prone newborn animals was associated with an increased occurrence of diabetes mellitus [37]. Intra-peritoneal immunization of salmon fish with vaccines embedded in oil-adjuvants also induced autoantibodies and the outbreak of granulomatous disease of the liver and peritoneum and immune mediated glomerulonephritis [38]. Specifically, regarding vaccination-induced autoimmunity of the CNS, application of unpurified rabies vaccine (which contained fragments of myelin with antigenic properties) was shown to induce encephalomyelitis. [31,39].

The exact pathophysiologic mechanism of post-vaccination optic neuritis is not clearly defined. It could be triggered by a common denominator such as the adjuvant [40] used in the vaccine to enhance the antigen-specific immune response. This phenomenon is well described under the umbrella term “autoimmune/ inflammatory syndrome induced by adjuvants” (ASIA) [24], which also includes the Gulf War syndrome, macrophagic myofascitis, siliconosis and others. Aluminium salts are the most widely used adjuvants in human vaccines [41]. There are many hypotheses concerning the booster mechanism of aluminum on the immune responses, including forming nodules slowly releasing antigen (“depot theory”) [42], role of the NACHT, LRR and PYD domains-containing protein-3 (Nlrp3) inflammasome, increased interleukin-4 production [43] release of uric acid [44] and activation of the Syk-PI3 kinase pathway [45-47]. Notably, the vast majority of adverse manifestations experimentally triggered by aluminum in animal models or associated with administration of adjuvanted vaccines in humans are neurological and neuropsychiatric. Interestingly, aluminum particles have a capacity to cross the blood-brain and blood-cerebrospinal fluid barriers and incite immunoinflammatory response in neural tissues [48,49]. Moreover, as the size of aluminum-adsorbed antigen complexes is greater than the molecular weight cut-off of the glomerulus, the effective clearance of aluminum from the body is impaired, resulting in accumulation of this particle in the organism [50]. In our analysis we have observed that vaccines containing aluminum were associated with delayed ON onset in comparison to aluminum – free injections, what may be explained by the delayed clearance of this particle after the vaccination. Interestingly, isolated ON was most frequently reported after influenza vaccine, which is aluminum-free, whereas vaccines containing this element were the leading causes of further demyelination of CNS (MS, NMOSD), what may support the theory of this adjuvant higher neurotoxicity. Nevertheless, the impact of MS cases associated with HBV vaccine increased reporting in VAERS due to increased media attention and public awareness on that topic influencing our results cannot be excluded.

Molecular mimicry is another theory explaining the enigmatic link between vaccines and autoimmunity, described in cases of HBV vaccine (mimicry with myelin basic protein 1) [51] and HPV vaccine (L1 HPV peptide homology to proteins associated with SLE [52].

The concept of molecular mimicry is based on the structural similarity between a pathogen or metabolite and self-structures. The similarity could be expressed as shared amino acid sequences or similar conformational structure between a pathogen and selfantigen [53]. The mimicry between Campylobacter jejuni and GM1 ganglioside antigen, one of the targets of the autoantibodies commonly present in GBS patients, served as a flagship example of this interplay. Interestingly, the association between GBS and Campylobacter jejuni infection was most staggeringly reported during the mass influenza immunization in the United States, prompted by ”swine flu” outbreak, as there was a significant increase in GBS incidence among the vaccinated population. Years later it was demonstrated that mice immunized with the vaccine developed antiganglioside antibodies (anti-GM1), thus supporting the hypothesis that molecular mimicry was the link between vaccine and disease [54]. Nevertheless, the study conducted by Nachamkin et al. in 2008 [55] shed a new light on that topic. In this experiment the vaccines used in 1976, as long as influenza vaccines from 1991-1992 and 2004-2005 were tested for presence of C. jejuni and the ability to induce anti-GM1 antibodies production in mice. Intriguingly, it was observed that none of the tested vaccines contained C. jejuni, although all of them contained glycolipid-like molecules and induced anti-GM1 antibodies in mice. This effect was reported as related to influenza virus hemagglutinin ability to induce anti-GM1. In our analysis we have observed that vaccination against influenza was the leading cause of isolated ON. Interestingly, the association of isolated ON with the presence of antiganglioside antibodies (GQ1b/GT1a) was reported in the literature, in coherence with the fact that the optic nerve is the second most concentrated area of these gangliosides [56]. Regrettably, in none of the case reports qualified to analysis in this study the presence of antiganglioside antibodies was tested, so further conclusions cannot be formulated, although this issue seems a promising area for future research [57-97].

Conclusion

Although it is difficult to establish a causal relationship between vaccination and optic neuritis, we nevertheless believe it is important to make such cases known, both to contribute to the continued development of safe and efficacious methods of vaccination, as well as to provoke further investigation into the pathogenesis of ON. Physicians should be aware of this rare adverse effect of vaccination and performing full antibody profile screening (anti-AQP4, anti- MOG, anti-ganglioside, anti-phosphatidylcholine) when patient presents symptoms of ON should be encouraged.

Conflict of Interest

JR declares no conflict of interest relevant to this study.

References

1. Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol. 2014;13:83-99.
2. Taylor B V, Lucas RM, Dear K. Latitudinal variation in incidence and type of first central nervous system demyelinating events. Mult Scler J. 2010;16:398-405.
3. Arnold ac. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol. 2005;139:1101-1108.
4. Schattner A, Voichanski S, Uliel L. SLE presenting as demyelinative autoimmune visual loss. BMJ Case Rep. 2018;2018:2017-222158.
5. Moulick A, Sarkar BS, Jana A, Guha P, Das A. Systemic sclerosis presenting with simultaneous retinal vasculitis in one eye and optic neuritis in the other along with severe immune haemolytic anaemia. J Clin Diag Res. 2013;7:2978-2980.
6. Cong H, Jiang H, Peng J. Change of Th17 lymphocytes and treg/th17 in typical and atypical optic neuritis. PLOS One. 2016;11:0146270.
7. Rossi S, Motta C, Studer V. Interleukin-8 is associated with acute and persistent dysfunction after optic neuritis. Mult Scler J. 2014;20:1841-1850.
8. Soelberg K, Nilsson AC, Nielsen C. Autoimmune and immunogenetic profile of patients with optic neuritis in a population-based cohort. Mult Scler Relat Disord. 2018;21:97-102.
9. Gershwin ME. The mosaic of autoimmunity. Autoimmun Rev. 2008;7:161-163.
10. Stübgen J-P. A literature review on optic neuritis following vaccination against virus infections. Autoimmun Rev. 2013;12:990-997.
11. Lai C-C, Chang Y-S, Li M-L, Chang C-M, Huang F-C, Tseng S-H. Acute anterior uveitis and optic neuritis as ocular complications of influenza a infection in an 11-year-old boy. J Pediatr Ophthalmol Strabismus. 2011.
12. Strong LE, Henderson JW, Gangitano JL. Bilateral retrobulbar neuritis secondary to mumps. Am J Ophthalmol. 1974;78(2):331-332.
13. Stergiou PK, Konstantinou IM, Karagianni TN, Kavaki D, Printza NG. Optic neuritis caused by varicella infection in an immunocompetent child. Pediatr Neurol. 2007;37:138-139.
14. Park KH, Bang JH, Park WB. Retrobulbar  optic neuritis and meningoencephalitis following progressive outer retinal necrosis due to cmv in a patient with aids. Infection. 2008;36:475-479.
15. Ogata N, Koike N, Yoshikawa T, Takahashi K. Human herpesvirus 6-associated uveitis with optic neuritis diagnosed by multiplex PCR. Jpn J Ophthalmol. 2011;55:502-505.
16. Purvin V, Herr GJ, De Myer W. Chiasmal neuritis as a complication of epstein-barr virus infection. Arch Neurol. 1988;45:458-460.
17. Matsunaga M, Kodama Y, Maruyama S. Guillain-Barré syndrome and optic neuritis after Mycoplasma pneumoniae infection. Brain Dev. 2018;40:439-442.
18. Jasiak-Zatonska M, Kalinowska-Lyszczarz A, Michalak S, Kozubski W. The immunology of neuromyelitis optica-current knowledge, clinical implications, controversies and future perspectives. Int J Mol Sci. 2016;17:273.
19. Pohl D, Alper G, Van Haren K. Acute disseminated encephalomyelitis. Neurology. 2016;87:38-45.
20. Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015;33:4398-4405.
21. Sukumaran L, McNeil MM, Moro PL, Lewis PW, Winiecki SK, Shimabukuro TT. Adverse events following measles, mumps, and rubella vaccine in adults reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013. Clin Infect Dis. 2015;60:58-65.
22. The 2nd BIO Rheumatology International Congress (BRIC)/ The 9th Global Arthritis Research Network (GARN) 2014 Meeting in Moscow. Int J Rheum Dis. 2014;17:6-29.
23. Watad A, Quaresma M, Brown S. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld’s syndrome): An update. Lupus. 2017;26:675-681.
24. Riikonen R. The role of infection and vaccination in the genesis of optic neuritis and multiple sclerosis in children. Acta Neurol Scand. 1989;80:425-431.
25. Korematsu S, Miyahara H, Kakita A, Izumi T. Elevated serum anti-phosphatidylcholine IgG antibodies in patients with influenza vaccination: Associated optic neuritis. Vaccine. 2014;32:6345-6348.
26. Chen RT, Pless R, Destefano F. Epidemiology of autoimmune reactions induced by vaccination. J Autoimmun. 2001;16:309-318.
27. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine. 2005;23:3876-3886.
28. Miravalle A, Biller J, Schnitzler E, Bonwit A. Neurological complications following vaccinations. Neurol Res. 2010;32:285-292.
29. Agmon-Levin N, Kivity S, Szyper-Kravitz M, Shoenfeld Y. Transverse myelitis and vaccines: A multi-analysis. Lupus. 2009;18:1198-1204.
30. Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev. 2014;13:215-224.
31. Bragazzi NL, Watad A, Amital H, Shoenfeld Y. Debate on vaccines and autoimmunity: Do not attack the author, yet discuss it methodologically. Vaccine. 2017;35:5522-5526.
32. Evans D, Cauchemez S, Hayden FG. Prepandemic immunization for novel influenza viruses, “Swine Flu” vaccine, guillain-barré syndrome, and the detection of rare severe adverse events.  J Infect Dis. 2009;200:321-328.
33. Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol. 2009;5:648-652.
34. Inbar R, Weiss R, Tomljenovic L. Behavioral abnormalities in female mice following administration of aluminum adjuvants and the Human Papillomavirus (HPV) vaccine Gardasil. Immunol Res. 2017;65:136-149.
35. Hogenesch H, Azcona-Olivera J, Scott-Moncrieff C, Snyder PW, Glickman LT. Vaccine-induced autoimmunity in the dog. Adv Vet Med. 1999;41:733-747.
36. Classen JB. The timing of immunization affects the development of diabetes in rodents. Autoimmun. 1996;24:137-145.
37. Koppang EO, Bjerkås I, Haugarvoll E. Vaccination-induced systemic autoimmunity in farmed Atlantic salmon. J Immunol. 2008;181:4807-4814.
38. Karussis D, Vourka-Karussis U, Mizrachi-Koll R, Abramsky O. Acute/relapsing experimental autoimmune encephalomyelitis: Induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation. Mult Scler. 1999;5:17-21.
39. Pellegrino P, Clementi E, Radice S. On vaccine’s adjuvants and autoimmunity: Current evidence and future perspectives. Autoimmun Rev. 2015;14:880-888.
40. De Gregorio E, Tritto E, Rappuoli R. Alum adjuvanticity: Unraveling a century old mystery. Eur J Immunol. 2008;38:2068-2071.
41. Harrison WT. Some observations on the use of alum precipitated diphtheria toxoid. Am J Public Health Nations Health. 1935;25:298-300.
42. Jordan MB, Mills DM, Kappler J, Marrack P, Cambier JC. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science. 2004;304:1808-1810.
43. Bianchi ME. DAMPs, PAMPs and alarmins: All we need to know about danger. J Leukoc Biol. 2007;81:1-5.
44. Flach TL, Ng G, Hari A. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med. 2011;17:479-487.
45. Mori A, Oleszycka E, Sharp FA. The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses. Eur J Immunol. 2012;42:2709-2719.
46. Kuroda E, Ishii KJ, Uematsu S. Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity. 2011;34:514-526.
47. Shaw CA, Petrik MS. Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration. J Inorg Biochem. 2009;103:1555-1562.
48. Gherardi RK, Eidi H, Crépeaux G, Authier FJ, Cadusseau J. Biopersistence and brain translocation of aluminum adjuvants of vaccines. Front Neurol. 2015;6:4.
49. Langer-Gould A, Qian L, Tartof SY. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol. 2014;71:1506.
50. Bragazzi NL, Bridgewood C, Sharif K. HPV vaccines and lupus: Current approaches towards preventing adverse immune cross-reactivity. Expert Rev Vaccines. 2019;18:31-42.
51. Blank M, Barzilai O, Shoenfeld Y. Molecular mimicry and auto-immunity. Clin Rev Allergy Immunol. 2007;32:111-118.
52. Segal Y, Shoenfeld Y. Vaccine-induced autoimmunity: The role of molecular mimicry and immune crossreaction. Cell Mol Immunol. 2018;15:586-594.
53. Nachamkin I, Shadomy S V, Moran AP. Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: Insights into vaccine-associated Guillain-Barré syndrome. J Infect Dis. 2008;198:226-233.
54. Biotti D, Boucher S, Ong E, Tilikete C, Vighetto A. Optic neuritis as a possible phenotype of anti-GQ1b/GT1a antibody syndrome. J Neurol. 2013;260:2890-2891.
55. ROSS JVM. Bilateral optic neuritis with partial internal ophthalmoplegia following administration of diphtheria toxoid, alum precipitated, refined. Eye Ear Nose Throat Mon. 1949;28:119-122.
56. Mcreynolds WU, Havener WH, Petrohelos MA. Bilateral optic neuritis following smallpox vaccination and diphtheria-tetanus toxoid. AMA Am J Dis Child. 1953;86:601-603.
57. Kazarian EL, Gager WE. Optic neuritis complicating measles, mumps, and rubella vaccination. Am J Ophthalmol. 1978;86:544-547.
58. Perry HD, Mallen FJ, Grodin RW, Cossari AJ. Reversible blindness in optic neuritis associated with influenza vaccination. Ann Ophthalmol. 1979;11:545-550.
59. Kline LB, Margulies SL, Oh SJ. Optic neuritis and myelitis following rubella vaccination. Arch Neurol. 1982;39:443-444.
60. Yen MY, Liu JH. Bilateral optic neuritis following Bacille Calmette-Guérin (BCG) vaccination. J Clin Neuroophthalmol. 1991;11:246-249.
61. Topaloglu H, Berker M, Kansu T, Saatci U, Renda Y. Optic neuritis and myelitis after booster tetanus toxoid vaccination. Lancet (London, England). 1992;339:178-179.
62. Ray CL, Dreizin IJ. Bilateral optic neuropathy associated with influenza vaccination. J Neuroophthalmol. 1996;16:182-184.
63. Stevenson VL, Acheson JF, Ball J, Plant GT. Optic neuritis following measles/rubella vaccination in two 13-year-old children. Br J Ophthalmol. 1996;80:1110-1111.
64. Hull TP, Bates JH. Optic neuritis after influenza vaccination. Am J Ophthalmol. 1997;124:703-704.
65. Albitar S, Bourgeon B, Genin R. Bilateral retrobulbar optic neuritis with hepatitis B vaccination. Nephrol Dial Transplant. 1997;12:2169-2170.
66. Kawasaki A, Purvin VA, Tang R. Bilateral anterior ischemic optic neuropathy following influenza vaccination. J Neuroophthalmol. 1998;18:56-59.
67. Stewart O, Chang B, Bradbury J. Simultaneous administration of hepatitis B and polio vaccines associated with bilateral optic neuritis. Br J Ophthalmol. 1999;83:1200-1201.
68. Burkhard C, Choi M, Wilhelm H. Optic neuritis as a complication in preventive tetanus-diphtheria-poliomyelitis vaccination: A case report. Klin Monbl Augenheilkd. 2001;218:51-54.
69. Dadeya S, Guliani BP, Gupta VS, Malik KPS, Jain DC. Retrobulbar Neuritis following Rabies Vaccination. Trop Doct. 2004;34:174-175.
70. Kerrison JB, Lounsbury D, Thirkill CE, Lane RG, Schatz MP, Engler RM. Optic neuritis after anthrax vaccination. Ophthalmol. 2002;109:99-104.
71. Arshi S, Sadeghi-bazargani H, Ojaghi H. The first rapid onset optic neuritis after measles-rubella vaccination: case report. Vaccine. 2004;22:3240-3242.
72. Kulkarni V, Nadgir D, Tapiawala S. Biphasic demyelination of the nervous system following anti-rabies vaccination. Neurol India. 2004;52:106-108.
73. Hegde V, Dean F. Bilateral panuveitis and optic neuritis following Bacillus Calmette-Guérin (BCG) vaccination. Acta Paediatr. 2007;94:635-636.
74. Huynh W, Cordato DJ, Kehdi E, Masters LT, Dedousis C. Post-vaccination encephalomyelitis: Literature review and illustrative case. J Clin Neurosci. 2008;15:1315-1322.
75. Laria C, Alió J, Rodríguez JL, Sánchez J, Galal A. Optic neuritis after meningococcal vaccination. Arch Soc Esp Oftalmol. 2006;81:479-482.
76. Menge T, Cree B, Saleh A. Neuromyelitis optica following human papillomavirus vaccination. Neurology. 2012;79:285-287.
77. Lapphra K, Huh L, Scheifele DW. Adverse neurologic reactions after both doses of pandemic H1N1 influenza vaccine with optic neuritis and demyelination. Pediatr Infect Dis J. 2011;30:84-86.
78. Huang EHZ, Lim SA, Lim PL, Leo YS. Retrobulbar optic neuritis after Hepatitis A vaccination in a HIV-infected patient. Eye. 2009;23:2267-2271.
79. Erguven M, Guven S, Akyuz U, Bilgiç O, Laloglu F. Optic neuritis following hepatitis b vaccination in a 9-year-old Girl. J Chinese Med Assoc. 2009;72:594-597.
80. DiMario FJ, Hajjar M, Ciesielski T. A 16-Year-old girl with bilateral visual loss and left hemiparesis following an immunization against human papilloma virus. J Child Neurol. 2010;25:321-327.
81. Furukawa Y, Komai K, Yamada M. Neuromyelitis optica after Japanese encephalitis vaccination. Eur J Neurol. 2011;18:26-27.
82. Crawford C, Grazko MB, Raymond WR, Rivers BA, Munson PD. Reversible blindness in bilateral optic neruritis associated with nasal flu vaccine. Binocul Vis Strabolog Q Simms Romano. 2012;27:171-173.
83. Kitazawa Y, Warabi Y, Bandoh M, Takahashi T, Matsubara S. Elderly-onset neuromyelitis optica which developed after the diagnosis of prostate adenocarcinoma and relapsed after a 23-valent Pneumococcal Polysaccharide Vaccination. Intern Med. 2012;51:103-107.
84. Rubinov A, Beiran I, Krasnitz I, Miller B. Bilateral optic neuritis after inactivated influenza vaccination. Isr Med Assoc J. 2012;14:705-707.
85. O’Dowd S, Bafiq R, Ryan A, Cullinane A, Costello D. Severe bilateral optic neuritis post Hepatitis A Virus (HAV) and typhoid fever vaccination. J Neurol Sci. 2015;357:300-301.
86. Ryu WY, Sohn EJ, Kwon YH. Acute disseminated encephalomyelitis without optic neuritis followed by optic neuritis in a child due to the sudden cessation of steroid therapy. Semin Ophthalmol. 2014;29:18-21.
87. Han SB, Hwang J-M, Kim J-S, Yang HK. Optic neuritis following Varicella zoster vaccination: Report of two cases. Vaccine. 2014;32:4881-4884.
88. Heekin R, Gandhy C, Robertson D. Seronegative neuromyelitis optica spectrum disorder following exposure to hepatitis b vaccination. Case Rep Neurol. 2015;7:78-83.
89. Schöberl F, Csanadi E, Eren O, Dieterich M, Kümpfel T. NMOSD triggered by yellow fever vaccination: An unusual clinical presentation with segmental painful erythema. Mult Scler Relat Disord. 2017;11:43-44.
90. Chang H, Lee HL, Yeo M. Recurrent optic neuritis and neuromyelitis optica-IgG following first and second human papillomavirus vaccinations. Clin Neurol Neurosurg. 2016;144:126-128.
91. De Giacinto C, Guaglione E, Leon PE. Unilateral optic neuritis: A rare complication after measles-mumps-rubella vaccination in a 30-year-old woman. Case Rep Ophthalmol Med. 2016;2016:8740264.
92. Cabrera-Maqueda JM, Hernández-Clares R, Baidez-Guerrero AE, Pío-Rendón JIB, Fernández JJM. Optic neuritis in pregnancy after Tdap vaccination: Report of two cases. Clin Neurol Neurosurg. 2017;160:116-118.
93. O’Brien P, Wong RW. Optic neuritis following diphtheria, tetanus, pertussis, and inactivated poliovirus combined vaccination: A case report. J Med Case Rep. 2018;12:356.
94. Jun B, Fraunfelder FW. Atypical optic neuritis after inactivated influenza vaccination. Neuroophthalmology. 2018;42:105-108.
95. Michael NDB, Tuan Jaffar TN, Hussein A, Wan Hitam W-H. Simultaneous bilateral optic neuritis following human papillomavirus vaccination in a young child. Cureus. 2018;10:3352.